The FDA approval of FAYUVI ... disease. As the first FDA-approved treatment for the condition, the single-dose AAV9 gene therapy establishes a new therapeutic option for a population that previously had no approved treatment. The clinical evidence supporting approval included the pivotal Transpher A trial and long-term ... The FDA approval of FAYUVI (rebisufligene etisparvovec) for pediatric patients with Sanfilippo syndrome type A marks a significant change in the treatment landscape for this progressive, fatal neurodegenerative disease. As the first FDA-approved treatment for the condition, the single-dose AAV9 gene therapy establishes a new therapeutic option for a population that previously had no approved treatment. The clinical evidence supporting approval included the pivotal Transpher A trial and long-term follow-up studies extending to nearly eight years. Recent results in hypophosphatasia (HPP) and ultra-rare cholestatic liver diseases illustrate how clinical evidence can strengthen or complicate a therapy’s competitive position, even when both programs address substantial unmet need. Efzimfotase alfa received FDA Priority Review for patients aged two years and older, with a regulatory decision anticipated in the first half of 2027. However, its HICKORY Phase III trial did not achieve statistical significance on the primary endpoint of the Six-Minute Walk Test at week 25. Lixudebart’s clinical validation: Results from the ongoing RENAL trial and subsequent development progress in FSGS and PSC, which will help determine whether the proposed multidisease strategy is supported by clinical evidence. Evidence of operational value from platform investments: Progress showing that manufacturing partnerships, expanded production capacity and AI-enabled RNA research are improving development execution or advancing therapeutic candidates. The defining shift in the rare disease market during this reporting period is the move from therapeutic promise toward demonstrable clinical value and practical delivery. The defining story of this reporting period is the transition of rare disease innovation from scientific and regulatory milestones toward proof of clinical value and practical patient access. The FDA approval of the first treatment for Sanfilippo syndrome type A, mixed Phase III evidence for an investigational hypophosphatasia therapy, and positive results in ultra-rare cholestatic liver diseases illustrate how differently this transition can unfold across indications.

Spruce’s lead product candidate, ... neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan ... Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. The strategic investment reflects a shared commitment among Spruce and two of the leading organizations serving the MPS and Sanfilippo communities to accelerate access to TA-ERT for the treatment of MPS IIIB, a devastating, rapidly progressing neurodegenerative disease that primarily affects children and for which there are no FDA-approved therapies. The Foundations’ and community fundraising efforts led to the initiation of EAP start-up activities earlier this year, including manufacturing of drug product, to accelerate access to children and families impacted by MPS IIIB in advance of potential U.S. The final stage of MPS IIIB is typically marked by severe dementia, loss of motor function, and seizure activity, with patients largely bed-ridden and requiring constant care, requiring feeding tubes for hydration and nutrition, and ultimately leading to death. The estimated life expectancy of individuals with MPS IIIB ranges from 15 to 19 years of age. Currently, there are no FDA-approved therapies for MPS IIIB, and management of the disease consists of limited palliative care to improve quality of life. As both a physician and a parent in this community, I know the urgency families feel as they watch this devastating disease take abilities from their children,” said Cara O’Neill, M.D., Chief Science Officer and Co-Founder of Cure Sanfilippo Foundation. “The encouraging clinical data for TA-ERT offer meaningful hope, and our investment reflects the Foundation’s deep commitment to advancing rigorous science while bringing promising therapies within reach for children who need time-sensitive access.

A recent study published in PubMed explores a rare neurodegenerative disorder characterized by regression, ataxia, and nystagmus in a toddler. This research contributes to the understanding of the clinical presentation and potential underlying mechanisms of this condition.

Spruce’s lead product candidate, ... neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan ... Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. Most recently, as Executive Medical Director, she served as clinical sciences lead for Brineura® (cerliponase alfa), an enzyme replacement therapy for CLN2 disease, a rare pediatric neurodegenerative disorder, leading study closeout and clinical study report development and supporting major regulatory milestones, including an FDA sBLA efficacy supplement approval, an EMA Type II variation approval and an MHRA post-authorization measure approval. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning clinical development, product portfolio development and medical affairs, with extensive experience in rare disease and a track record of supporting global regulatory approvals for enzyme replacement therapies, including for rare pediatric neurodegenerative disorders. She brings significant experience in rare genetic diseases having spent her career developing and supporting therapies for children with rare genetic and neurodegenerative diseases, including leading clinical sciences for an enzyme replacement therapy for a rare pediatric neurodegenerative disorder,” said Adrian Quartel, M.D., FFPM, Chief Medical Officer of Spruce Biosciences.